WallStreetZenWallStreetZen

NASDAQ: LYRA
Lyra Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LYRA

Based on 1 analyst offering 12 month price targets for Lyra Therapeutics Inc

Min Forecast
$16.00+798.88%
Avg Forecast
$16.00+798.88%
Max Forecast
$16.00+798.88%

Should I buy or sell LYRA stock?

Based on 1 analyst offering ratings for Lyra Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LYRA stock forecasts and price targets.

LYRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-14

1 of 1

Forecast return on equity

Is LYRA forecast to generate an efficient return?

Forecast return on assets

Is LYRA forecast to generate an efficient return on assets?

Company
N/A
Industry
122.26%

LYRA earnings per share forecast

What is LYRA's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$7.16
Avg 2 year Forecast
-$6.48

LYRA revenue forecast

What is LYRA's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.7M+189%
Avg 2 year Forecast
$11.7M+1,849%
Avg 3 year Forecast
$37.4M+6,127.5%
LYRA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LYRA revenue growth forecast

How is LYRA forecast to perform vs Biotechnology companies and vs the US market?

Company
286.47%
Industry
116.92%
Market
23.08%
LYRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LYRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LYRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LYRA$1.78$16.00+798.88%Hold
INM$1.10N/AN/A
CMND$2.17N/AN/A
PPCB$0.23N/AN/A
AIM$1.15$22.00+1,813.04%Buy
View Top Biotech Stocks

Lyra Therapeutics Stock Forecast FAQ

Is Lyra Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LYRA) stock is to Hold LYRA stock.

Out of 1 analyst, 0 (0%) are recommending LYRA as a Strong Buy, 0 (0%) are recommending LYRA as a Buy, 1 (100%) are recommending LYRA as a Hold, 0 (0%) are recommending LYRA as a Sell, and 0 (0%) are recommending LYRA as a Strong Sell.

If you're new to stock investing, here's how to buy Lyra Therapeutics stock.

What is LYRA's earnings growth forecast for 2026-2027?

(NASDAQ: LYRA) Lyra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Lyra Therapeutics's earnings in 2026 is -$32,947,000.On average, 4 Wall Street analysts forecast LYRA's earnings for 2026 to be -$12,708,865, with the lowest LYRA earnings forecast at -$12,210,478, and the highest LYRA earnings forecast at -$13,082,655.

In 2027, LYRA is forecast to generate -$11,495,911 in earnings, with the lowest earnings forecast at -$11,045,091 and the highest earnings forecast at -$11,834,026.

What is LYRA's revenue growth forecast for 2026-2028?

(NASDAQ: LYRA) Lyra Therapeutics's forecast annual revenue growth rate of 286.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Lyra Therapeutics's revenue in 2026 is $600,000.On average, 4 Wall Street analysts forecast LYRA's revenue for 2026 to be $3,077,645, with the lowest LYRA revenue forecast at $1,217,569, and the highest LYRA revenue forecast at $5,031,790. On average, 3 Wall Street analysts forecast LYRA's revenue for 2027 to be $20,755,470, with the lowest LYRA revenue forecast at $19,942,574, and the highest LYRA revenue forecast at $21,366,030.

In 2028, LYRA is forecast to generate $66,318,466 in revenue, with the lowest revenue forecast at $63,716,489 and the highest revenue forecast at $68,269,061.

What is LYRA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: LYRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 122.26%.

What is LYRA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year LYRA price target, the average LYRA price target is $16.00, with the highest LYRA stock price forecast at $16.00 and the lowest LYRA stock price forecast at $16.00.

The Wall Street analyst predicted that Lyra Therapeutics's share price could reach $16.00 by Aug 14, 2026. The average Lyra Therapeutics stock price prediction forecasts a potential upside of 798.88% from the current LYRA share price of $1.78.

What is LYRA's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: LYRA) Lyra Therapeutics's current Earnings Per Share (EPS) is -$23.39. On average, analysts forecast that LYRA's EPS will be -$7.16 for 2026, with the lowest EPS forecast at -$6.88, and the highest EPS forecast at -$7.37. In 2027, LYRA's EPS is forecast to hit -$6.48 (min: -$6.22, max: -$6.67).

What is LYRA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: LYRA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.